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Abstract
Geldanamycin derivatives are benzoquinone ansamycin antibiotics that bind to Hsp90 and alter its function. The alteration
of Hsp90 activity limits some cellular hormonal responses by inhibiting nuclear receptors activation. The nuclear receptors
activity, such as PPARc, the mineralocorticoid and glucocorticoid receptors (MR and GR) play a critical role in the conversion
of preadipocytes to mature adipocytes. Given the importance of these nuclear receptors for adipogenesis, we investigated
the effects of geldanamycin analogues (GA) on adipocyte differentiation and function. We found that early exposure of
preadipocyte cells to GA inhibited their conversion into mature adipocytes by inhibiting the adipogenic transcriptional
program and lipid droplets accumulation. Furthermore, GA altered the adipokines secretion profile of mature adipocyte.
The anti-adipogenic effect of GA was also confirmed in mice fed a high fat diet. Biochemical analysis revealed that anti-
adipogenic effects of geldanamycin analogues may result from the simultaneous inhibition of MR, GR and PPARc activity.
Taken together, our observations lead us to propose Hsp90 as a potent target for drug development in the control of
obesity and its related metabolic complications.
Citation: Desarzens S, Liao W-H, Mammi C, Caprio M, Faresse N (2014) Hsp90 Blockers Inhibit Adipocyte Differentiation and Fat Mass Accumulation. PLoS
ONE 9(4): e94127. doi:10.1371/journal.pone.0094127
Editor: Didier Picard, University of Geneva, Switzerland
Received October 11, 2013; Accepted March 14, 2014; Published April 4, 2014
Copyright:  2014 Desarzens et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The study was supported by funding form the Swiss National Science Foundation (Ambizone grant PZ00P3_142594) and the National Centre of
Competence in Research (NCCR) Kidney.CH. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the
manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: nourdine.faresse@uzh.ch
Introduction
Adipogenesis represents the complex cascade of events leading a
preadipocyte to acquire the feature of a mature adipocyte. It
occurs as a consequence of normal cell turnover, and contribute to
adipose tissue expansion in response to hormonal cues and calorie
surplus [1]. Excess adipocyte size or number leads to obesity,
which is a hallmark of metabolic syndrome (MetS) that includes
hypertension, diabetes and dyslipidemia [2]. Obesity affects
around 300 million individuals worldwide, a number that is
expected to grow continuously in the next years, making obesity
and MetS a priority in health expenses [3].
Several hormones and growth factors induce adipogenesis
through a tightly controlled transcriptional cascade involving the
sequential activation of CCAAT/enhancer binding proteins (C/
EBPs) and peroxisome proliferator-activated receptor c (PPARc)
[4]. Briefly, C/EBPb and d induce the expression of PPARc which
is responsible for inducing C/EBPa. Once initiated, this cascade
will maintain the expression of these critical transcription factors
thanks to a positive feedback loop where C/EBPa and PPARc
reciprocally reinforce their expression [4].
The mineralocorticoid (MR) and glucocorticoid receptors (GR)
are expressed in adipocytes and are both involved in adipogenesis.
Given the lack of 11bHSD2 in adipocytes, these two receptors can
be activated by glucocorticoids [5]. In their non-activated state,
these receptors are predominantly cytoplasmic and part of a large
heteromeric complex interacting with a number of proteins.
Among these, the chaperone protein Heat Shock Protein 90
(Hsp90) is the best characterized. Chaperone proteins play an
important role in the conversion of misfolded proteins to a
functional conformation. In the case of MR/GR, their association
with Hsp90 is crucial for proper ligand binding and receptor
function. Indeed, it was shown that disruption of this interaction
by geldanamycin, a benzoquinone ansamycin antibiotic, leads to
decreased MR and GR mediated transcription [6,7,8]. Upon
ligand binding, these interactions are disrupted and the cytoplas-
mic complex is dissociated allowing the translocation of MR/GR
into the nucleus to regulate transcription of target genes.
GR is critical for the early adipogenesis [9], but serves a
relatively minor role in terminal differentiation. In vitro studies
showed that knock-down of MR and not GR in 3T3-L1 cells
affects the differentiation induced both by mineralocorticoids and
glucocorticoids [10,11]. Contradictory findings were observed in
primary human preadipocytes where suppression of GR but not
MR blocked glucocorticoids mediated adipogenesis [12]. In
addition, studies in animal models of obesity (ob/ob and db/db
mice) showed an increase in MR expression levels in adipose tissue
and a reversion of adipocyte dysfunction after treatment with MR
blockers [13,14]. These observations make MR and GR
interesting targets for limiting adipose tissue expansion and
consequently the appearance of MetS. Interestingly, it was found
that MR blockers spironolactone or eplerenone attenuate obesity-
related insulin resistance and inflammation [13,14]. Recently,
drospirenone, a powerful anti-mineralocorticoid with progesto-
genic activity, has been shown to exert an antiadipogenic effect
related to an alteration of MR activation [11].
Geldanamycin and its analogues (17-AAG and 17-DMAG)
block Hsp90 activity and consequently inhibit nuclear receptors
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activation by decreasing their expression levels [7,8]. Numerous
preclinical data and multiple phase I and II trials reported safety
and promising activity of geldanamycin analogues (GA) in cancer
treatment [15,16,17,18,19]. Given the pharmacological profile of
GA and the adipogenic role of MR, GR and PPARc, we
hypothesized that GA prevent adipogenesis and adipocyte
function. Very recently, two concomitant in vitro studies described
the anti-adipogenic effects of Hsp90 blockers on 3T3-L1 cells
[20,21]. In the study of He et al., the authors showed that
Radicicol, a Hsp90 blocker, inhibited 3T3-L1 differentiation
through affecting the PDK1/Akt pathway, leading to the
inhibition of mitotic clonal expansion [20]. In the study of Nguyen
et al., the authors showed that Hsp90 blockers (geldanamycin and
novobiocin), inhibit adipocyte differentiation by inducing the
destabilization of PPARc at the protein level [21]. In this study, we
found that GA inhibits the adipocyte differentiation and function
in vitro and fat mass accumulation in vivo. This inhibition could be
the result of a decrease in GR and PPARc expression levels and an
inhibition of MR activation. Taken together, the beneficial effects
of Hsp90 inhibitors in fat mass accumulation provide a new
direction for MetS treatment.
Material and Methods
Cell culture
Murine 3T3-L1 and 3T3-F442A preadipocytes were cultured in
standard medium containing DMEM and 10% FCS. At
confluence, the differentiation process of 3T3-F442A cells was
initiated using DMEM 10% FCS supplemented with 10 mg/ml
insulin for 2 days, and then grown in standard medium for
additional 6 days. For 3T3-L1 cells, the differentiation was
initiated at confluence by stimulation with 500 mM 3-isobutyl-1-
methylxanthine, 10 mg/ml insulin and 1 mM dexamethasone for 2
days. Cells were then grown in DMEM 10% FCS supplemented
with 10 mg/ml insulin for additional 8 days. 17-AAG treatment at
indicated dose was started from the beginning of the differentiation
process. For primary cells culture, gonadal fat was extracted and
digested with collagenase type I (1 mg/ml) for 30 min. The totality
of the digestion mixture was seeded in an upside down T 25 cm2
flasks completely filled with DMEM and 20% FCS in presence or
absence of 17-AAG. After 4 days allowing the cells attachment, the
flasks were putted back in normal position and cells were grown
using standard culture conditions in 37uC 5% CO2 for 10 days.
Oil red-O staining
For determination of lipid content, differentiated cells were fixed
in 4% paraformaldehyde in PBS, washed twice with water and
stained with oil red-O. After oil red-O removal and washes once
with 60% isopropanol and twice with water, cells were visualized
under light microscopy. To quantify the lipid content, the stained
cells were permeabilized with 10% SDS and the eluate was
measured using spectrophotometer at 520 nm.
Cell cycle and viability
For flow cytometric determination, cells were trypsinized and
fixed in 70% ethanol. Fixed cells were stained with Propidium
Iodide, and analyzed on a FACScan flow cytometer. For the cell
viability the medium and attached cells were collected and death
cell were visualized using the trypan blue dye exclusion method.
Lipolysis assay
Differentiated 3T3-L1 adipocytes were cultured for 48 h with or
without 17-AAG (100 nM) in serum free medium and then treated
or not with 1 mM isoproterenol for 2 h. Medium was collected and
the glycerol released was measured by a colorimetric method using
a Free glycerol assay kit (Cell Biolabs).
Glucose uptake
Differentiated adipocytes were cultured for 48 h with or without
17-AAG (100 nM). Cells were washed with Krebs-Ringer buffer
containing 12 mM HEPES (KRH) and then treated with insulin
(100 nM) for 20 min. Glucose uptake was initiated by addition of
1 mCi/well of [3H]-Deoxy-D-glucose for 10 min and stopped by
washing cells 3 times with ice-cold KRH. Cells were lysed with
0.1 M NaOH and radioactivity was measured by scintillation
counting. In parallel, the protein concentration of the different
wells was evaluated by Bradford method.
Real-time quantitative PCR
Total RNA of adipocyte was extracted using the NucleoSpin
RNA (Macherey-Nagel) and was reverse transcribed using
RevertAidTM cDNA Synthesis Kit (Thermo Scientific). Sequenc-
es of primers are indicated in the Table S1. Quantitative PCR was
performed in replicate for each sample in a Light Cycler 480 Real-
Time PCR System by using Master I SYBR Green qPCR Master
Mix (Roche) according to the manufacturer’s instructions. Relative
amounts of mRNA were determined using the Comparative CT
Method for quantification and were normalized to GAPDH
mRNA expression.
Immunoblotting and adipokines array
Cells and tissue extracts were prepared as previously described
and 30 mg of protein extracts were loaded for SDS-PAGE [22].
The antibodies used were: anti-MR (1/100; kindly provided by
Gomez-Sanchez CE), anti-GR (1/1000 Santa Cruz), anti-SGK1
(1/1000 Sigma), anti-HSP90 (1/1000 Cell Signaling), anti-PPARc
(1/500 Cell Signaling), anti-CEBPa (1/500 Cell Signaling) and
anti-actin (1/1000 Sigma).
For the adipokine array, cell supernatants were assessed
following manufacturer’s instructions (Mouse Adipokines Array
Kit, R&D System). Briefly, supernatants from 6 independent
experiments were collected and pooled in 2 aliquots (pre-
adipocytes and mature adipocytes). 300 ml of the collected
medium was incubated over-night with the adipokine antibody
cocktail and the blocked nitrocellulose membrane. After several
washes, detection was performed using a chemi-luminescence kit
and autoradiography films. Quantification of the immunoblots
was performed using ImageJ software (NIH).
Animal experiments
Animal studies were carried out in accordance with Swiss
animal welfare regulations and after evaluation and written
consent of the veterinarian office of the Canton of Vaud,
Switzerland (license number 2591.0).Sixteen adult male C57BL/
6 mice were divided into 2 groups, one group as vehicle control
and the other one treated with 17-DMAG (LC Laboratories).Dur-
ing the experiment, mice were fed with high fat diet (60% of
calories derived from fat, Research Diet) and received daily
intraperitoneal injection with PBS or 17-DMAG 10 mg/kg of
body weight dissolved in PBS. The mice body weight was assessed
every 3 days. After 33 days, the body composition was analyzed on
individual mouse under light gaz anesthesia (isoflurane), by
quantitative nuclear magnetic resonance using an EchoMRI
Analyzer (EchoMedical Systems, Houston, TX). Data for individ-
ual mice were obtained by averaging results from two consecutive
measurements. Then, mice were placed in metabolic cages to
measure body weight, water/food consumption and urine
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collection for 3 days. Urinary Na+ and K+ were measured using a
flame photometer (Cole-Palmer Instruments, Vernon Hills,
IL).Mice were then anesthetized by isoflurane inhalation for blood
collection and euthanized by cervical dislocation for tissue
collection. Plasma glucose, triglycerides, cholesterol were mea-
sured by the Clinical Chemistry Lab of the University Hospital in
Lausanne using standard techniques.
Histological analysis
The epididymal and inguinal adipose tissue was fixed with 4%
paraformaldehyde in PBS and embedded in paraffin blocs. 10 mm
sections were stained with hematoxylin and eosin. Images were
acquired under light microscope and the size of adipocytes was
determined using ImageJ software (NIH).
Data analysis
All the experiments are done at least twice, and the
representative immunoblots were shown. For all histograms the
data are shown as the average 6 SD of results of at least three
independent experiments. Differences between test and control
conditions were assessed by Student’s t test analysis or Wilcoxon
signed rank test.
Figure 1. Geldanamycin analogues inhibit lipid accumulation in adipocytes. (A) At confluence, 3T3-L1 preadipocytes were induced to
differentiation in presence of an increasing dose of 17-AAG for 9 days. Lipid accumulation was visualized under microscope after Oil-Red-O staining
(scale bar, 70 mm) and (B) quantified after extraction of the stained lipid and the absorbance measured at 520 nm. The cell viability was assessed by
Trypan blue staining. Data are given as mean6 SD (n = 3), *p,0.05, ***p,0.001respect to untreated (C) Differentiating 3T3-L1 cells were cultured for
3 days with or without 17-AAG (100 nM). Cell cycle was determined on FACScan. Given data are representative of 2 independent experiments
performed in triplicate. (D) 3T3-L1 preadipocytes were induced to differentiation and treated with 17-AAG (100 nM) at the indicated day. At day 10,
lipid accumulation was stained with Oil-Red-O and quantified. Data are given as mean 6 SD (n = 3), *p,0.05, ***p,0.001
doi:10.1371/journal.pone.0094127.g001
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Results
Hsp90 blockade inhibits lipids accumulation in
adipocytes cells in vitro
To investigate the potential anti-adipogenic effect of Hsp90
blockade, preadipocyte 3T3-L1 cells were differentiated into
mature adipocytes in the presence of an increasing dose (from
1029 to 1026 M) of the DMSO soluble geldanamycin analogue17-
AAG. Treatment of adipocytes at the beginning of the differen-
tiation process with 17-AAG inhibited lipid accumulation assessed
by oil red-O staining in a dose dependent manner (Figure 1A and
B). Similar results were obtained using the water soluble
geldanamycin analogue 17-DMAG (Figure S1A and B).
To assess the cytotoxic effects of 17-AAG on preadipocytes, we
first evaluated the cellular viability by trypan blue assay. We found
that concentrations higher than 500 nM induced more than 50%
of cell death (Figure 1B). The evaluation of the cellular cycle by
FACS analysis showed that the apoptotic fraction dramatically
increases with high concentration of 17-AAG (1 mM). Addition-
ally, 17-AAG added in the first days of differentiation inhibited the
clonal expansion (G2/M phase) initiated by the differentiation
medium (Figure 1C). Due to its significant inhibition on lipid
accumulation and the minimal toxicity, the dose of 100 nM was
used for all the subsequent in vitro experiments.
Finally, to determine the critical time frame for the adipogenesis
inhibition by 17-AAG, we treated differentiating adipocytes at
different time points. We found that 17-AAG treatments after the
day 2 post-induction have no effect on the cellular lipid
accumulation (Figure 1D).
Figure 2. Hsp90 inhibition decreases the adipogenic transcriptional program without any effect on cytotoxicity. (A) Primary
preadipocytes derived from white adipose tissue (WAT) of mouse gonadal fat were cultured for 10 days with 17-AAG (300 nM) or DMSO (Control) and
visualized by microscopy 40X (scale bar: 50 mm). (B) Mature 3T3-L1 were cultured for 2 days with or without 17-AAG (100 nM) and tested for an
additional 2 h for lipolysis in response to 1 mM of isoproterenol. (C) 3T3-L1 cells were induced to differentiation in presence of 17-AAG for 2 days then
tested for [3H]-Deoxy-D-glucose uptake for 10 min. (D) 3T3-L1 preadipocytes were induced to differentiation in presence or absence of 17-AAG for 10
days. The abundance of CEBPa, PPARc, LPL and Glut4 mRNA in 3T3-L1 cells was measured by quantitative RT-PCR. Given are means relative to GAPDH
of 3 experiments performed in duplicates6 SEM, **p,0.01. (E) Cell lysates were analyzed by immunoblotting using antibodies against Hsp90, PPARc,
CEBPa and actin as a loading control. (F) The protein expression levels were quantified and values are given as mean 6 SEM (n= 6), **p,0.01.
doi:10.1371/journal.pone.0094127.g002
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The adipogenic transcriptional program is repressed by
Hsp90 blockers
The relevance of our findings on 3T3-L1 cells were confirmed
in the 3T3-F442A cells, a cell line able to differentiate into fat pads
in vivo [23], and in primary culture of mouse preadipocytes (Figure
S1A and B). Chronic exposure of primary cells derived from
epididymal fat to 17-AAG dramatically decreased the number and
size of lipid droplets inside these cells (Figure 2A). This effect on
cellular fat accumulation was not due to an increase of lipolysis
given that 17-AAG treatment did affect neither basal nor
isoproterenol induced lipolysis (Figure 2B). The insulin-induced
glucose uptake, another feature promoted during adipogenesis,
was also inhibited in presence of 17-AAG (Figure 2C).
To confirm that inhibition of lipid accumulation by 17-AAG
was due to the inhibition of adipocyte differentiation, we assessed
the expression of different molecular markers of adipogenesis in
3T3-L1 cells. By quantitative RT-PCR, we found that 17-AAG
significantly decreased the expression of PPARc which is a key
transcription factor in adipogenesis, as well as its downstream
targets lipoprotein lipase (LPL) and GLUT4 (Figure 2D). The
reduction of the other master regulator of adipogenesis CEBPa at
the RNA and protein level was not significant (Figure 2D to F).
The expression level of the direct target of geldanamycin Hsp90
did not change in presence of 17-AAG (Figure 2E).
Figure 3. Geldanamycin analogues limit high-fat diet-induced adipose tissue expansion. (A to F) Two groups of mice HFD (n= 7) and
HFD+17-DMAG (n= 8) were fed a HFD for 33 days and daily injected intraperitoneally with PBS or with 10 mg/kg of BW 17-DMAG. One group as
control ND (n = 4) were fed with standard chow. (A) Percentage of body weight (BW) gain was measured. (B) Body composition of the mice fed with
HFD or HFD+17-DMAG was evaluated by EchoMRI. (C) Histological analysis of the epididymal adipose tissue fixed and stained with hematoxylin and
eosin. (D) Adipocytes cell surface was calculated using the ImageJ software, ***p,0.001. (E) White adipose tissue lysates were submitted to
immunoblotting using antibodies against PPARc, CEBPa and actin as a loading control. (F) The protein expression levels were quantified and values
are given as mean 6 SEM (n= 7 HFD, n= 8 HFD+17-DMAG), **p,0.01.
doi:10.1371/journal.pone.0094127.g003
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Geldanamycin analogues prevent the high fat diet-
induced fat expansion
Given the antiadipogenic effects of geldanamycin analogues in
vitro and the recently published observations on amelioration of
obesity-induced renal failure by geldanamycin derivatives [24], we
investigated whether geldanamycin analogues could modulate fat
mass accumulation in vivo. C57BL6/N male mice were fed a HFD
and treated with the water soluble 17-DMAG (10 mg/kg/day) to
prevent side effects due to the solvent. After confirming that this
selected dose had no effect on body weight in mice on normal
chow diet, the geldanamycin analogue was injected intra-
peritoneally daily for 33 days according to previously published
pharmacokinetics data [25,26]. We found that mice treated with
17-DMAG showed a significantly lower body weight (BW) gain
compared to vehicle treated mice (Figure 3A, Figure S2). The
injection of 17-DMAG has no significant effect on food intake,
feces or urine production (Table 1), suggesting that at this selected
dose, 17-DMAG did not cause anorexia, digestive or renal
disorders. In addition, no major differences were observed
concerning the locomotor activity, the behavior or depression
between the 2 groups.
To examine whether the restricted BW gain was due to a
limited fat mass accumulation, we evaluated the whole-body
composition of the two groups of mice by EchoMRI. As shown in
Figure 3B, the fat mass was significantly decreased (around 40%)
in 17-DMAG treated mice, but not the lean mass or the total body
water. Histological analysis of the epididymal adipose tissue
revealed smaller and less heterogeneous adipocyte size in treated
mice (Mean size 14830.3 mm2 SE=282 vs. 8137.5 mm2 SE=222)
(Figure 3C and D). The same observations were done in the
inguinal fat pad (Figure S3). Blood samples analysis revealed also a
tendency towards reduction of glucose, triglycerides and choles-
terol with values comparable to mice fed a normal fat diet
(Table 1).
In accordance with 17-AAG effects in vitro, the expression levels
of the master adipogenic transcriptional factors revealed a
dramatic reduction of PPARc and to lower extent CEBPa in fat
tissue of mice treated with Hsp90 blocker (Figure 3E and 3F).
Hsp90 blockers affect MR and GR expression in vitro and
in vivo
It is known that geldanamycin analogues display a potent
inhibitory effect on MR and GR activity [6,7,8]. To evaluate the
effects of geldanamycin analogues treatment on these key Hsp90-
bound receptors involved in adipogenesis, we first determined the
expression level of MR and GR levels in mature 3T3-L1
adipocytes treated or not with 17-AAG from the beginning of
the differentiation process. 17-AAG treatment decreased the
expression of GR (Figure 4A and 4B), as it was described
previously in other cell types [7]. Regarding MR, the expression
profile diverged between the two conditions. In untreated cells,
MR appeared as a doublet on immunoblot and 17-AAG treatment
caused the disappearance of the upper band without major effects
on the expression of the lower band (Figure 4A and 4B). The same
observation was made with the specific MR blocker spironolactone
(Figure S4A). However, higher doses of 17-AAG induced also a
decrease in MR expression level (Figure S4B). Then we performed
a time-course experiment to follow the expression pattern of MR
during the differentiation process. As shown in Figure 4C, the
upward shift of MR was clearly visible at day 9 after confluency
and this modification was prevented by 24 h of 17-AAG
treatment. We have recently demonstrated that the upper band
represents the phosphorylated activated form of MR, which is
induced after ligand binding [22]. To confirm this observation, we
treated preadipocytes with MR ligands 10 nM aldosterone or
10 nM corticosterone in the presence or absence of 17-AAG.
Steroid stimulations induced the phosphorylation of MR, as
evidenced by an upward shift that was completely abolished by 17-
AAG treatment (Figure 4D). Given that the final maturation steps
of adipocyte differentiation were done in absence of hormones, our
results suggested an autocrine steroids stimulation that could
endogenously activate MR. This observation confirmed a recent
study showing the existence of an autocrine steroids production in
mature adipocytes [27].
To verify these observations in vivo, we evaluated the expression
levels of MR and GR in fat tissue of mice treated or not with 17-
DMAG. The treated group presented a marked reduction of GR
expression of about 80% in adipose tissue compared to the control
(Figure 4E and 4F). Of interest, the adipose expression of MR
increased in mice treated with 17-DMAG conversely to what was
observed in 3T3-L1 and 3T3-F442A adipocytes in vitro (Figure 4E
and 4F).
Geldanamycin analogues inhibit MR, GR and PPARc
transcriptional activity
We have seen that reduction of PPARc expression by
geldanamycin analogues leads to a reduction in the expression
of endogenous target genes like Glut4 or LPL (Figure 2C). The
inhibition of MR phosphorylation and the decrease in GR
expression level also abolished the steroidal induction of early
target genes such as Sgk1 (Figure 4D). To confirm the effects of
Hsp90 blockers on the transcriptional activity of MR, GR and
PPARc, we performed a luciferase reporter gene assay on mature
3T3-L1 cells. We found that the induction of the MMTV-luc
reporter gene by 100 nM aldosterone was completely abolished by
17-AAG at similar extent as the MR inhibitor spironolactone
(Figure 5A). To evaluate the specific GR activity, we used the same
luciferase reporter gene and we co-stimulated the cells with
100 nM dexamethasone (that binds to GR and MR) and 1 mM
spironolactone to suppress MR activity. We found that GR
activation was also repressed by 17-AAG in a similar manner as
the specific GR blocker RU486 (Figure 5B). Finally, to assess
Table 1. Effects of GA treatment on physiological parameters
of mice fed with HFD.
NFD HFD HFD+17-DMAG p
Food Intake (g/
24 h)
3.6660.33 3.8060.10 4.0060.09 0.508
Feces (g/24 h) 1.4060.30 0.3360.06 0.3760.05 0.680
Urine/Water (24 h) 0.1860.06 0.3060.08 0.3360.08 0.433
Plasma
Glucose (mM) 10.8360.85 13.4760.83 10.8860.60 0.056
Triglycerides (mM) 1.0360.11 1.0860.14 0.9460.07 0.514
Cholesterol (mM) 4.0660.22 4.1760.17 3.9660.13 0.159
Urine
Na+ (mmol/24 h) n.m 112.98615.56 111.78613.92 0.928
K+ (mmol/24 h) n.m 267.79635.06 296.78631.36 0.623
Values are given as average 6 SEM. The given P values for HFD vs. HFD+17-
DMAG.
doi:10.1371/journal.pone.0094127.t001
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PPARc activity, we found that 17-AAG as the PPARc specific
blocker T0070907 prevented the PPRE-luc reporter gene
induction by 1 mM Rosiglitazone (Figure 5C).
It has been previously described that early exposure to
aldosterone and dexamethasone enhance adipocyte differentiation
and promote PPARc expression [5,10]. Therefore, we assessed the
effect of Hsp90 blockers on the aldosterone and dexamethasone
induced PPARc expression. We found that treatment with 17-
AAG from the beginning of the differentiation process, signifi-
cantly inhibited the steroidal induction of PPARc mRNA
expression (Figure S5). Then, to evaluate the respective role of
MR and GR as well as the importance of 17-AAG inhibition in
the early steps of adipogenesis, we treated 3T3-L1 cells with
spironolactone (1 mM) or RU486 (1 mM) alone or in combination
with 17-AAG (100 nM) for the first 3 days of the differentiation
protocol. We found that spironolactone treatment, but not
RU486, significantly reduced lipid accumulation at day 9. Early
exposure of cells to 17-AAG also reduced lipid accumulation, and
such effect was further enhanced by spironolactone (Figure 5D).
To corroborate our findings at molecular level, we studied the
effect of early 17-AAG, spironolactone and RU486 treatment on
PPARc expression. As shown in Figure 5E, all these compounds
decreased PPARc mRNA level; however, the inhibitory effect of
17-AAG was enhanced only by spironolactone. These results
suggest that in addition to block the activity of PPARc,
geldanamycin analogues prevent its early de novo synthesis
mediated by MR and/or GR.
Figure 4. Geldanamycin analogues affect glucocorticoid receptors expression. (A to C) 3T3-L1 preadipocytes were induced to
differentiation with or without 17-AAG (100 nM) for 10 days. (A and B) Cell lysates were analyzed by immunoblotting using antibodies against MR, GR
and actin asa loading control. (B) The MR and GR expression level was quantified and values were normalized to actin and displayed as mean 6 SD
(n = 3), *p,0.05, **p,0.01. (C) 3T3-L1 preadipocytes were induced to differentiation and lysed at indicated day with or without 17-AAG treatment
(100 nM) for 24 h. (D) Preadipocytes were treated with aldosterone (10 nM) or corticosterone (10 nM) with or without 17-AAG (100 nM) for 3 h
before lysis. Cell lysates were then analyzed by immunoblotting using antibodies against MR, GR, and actin as a loading control. (E) White adipose
tissue lysates from HFD or HFD+17-DMAG mice were submitted to immunoblotting using antibodies against MR, GR and actin as a loading control.
(F) The protein expression levels were quantified and values are given as mean 6 SEM (n= 7 HFD, n = 8 HFD+17-DMAG), *p,0.05.
doi:10.1371/journal.pone.0094127.g004
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Inhibition of Hsp90 activity affects the production of
adipokines
It is well documented that the secretion profile of adipocytes
varies depending on their differentiation state or hormonal
stimulation [28]. To determine the effect of Hsp90 inhibition on
adipokines production, we first identified the differentially secreted
adipokines in the cell culture supernatants from 3T3-L1 pre-
adipocytes or mature adipocytes. Using an adipokine array, we
found 8 adipokines that were up-regulated in mature adipocyte
cells compared to preadipocytes (Figure 6A and 6B). Then we
evaluated the expression of these identified adipokines in 3T3-L1
cells treated or not with 17-AAG from the beginning of the
differentiation process. As shown in Figure 6C, 17-AAG treated
cells presented a significant reduced expression of all the tested
adipokines and displayed an adipokine profile close to the non-
differentiated cells. To test whether GA could affect the adipokine
Figure 5. Hsp90 blockers inhibitMR, GR and PPARc transcriptional activity in adipocytes. (A to C) Mature 3T3-L1 cells were co-transfected
by Metafectene with the reporter genes MMTV-luc (for A and B), PRE-luc (for C), and the constitutive luciferase vector coding for Renilla. After 30 h,
cells were exposed to the indicated treatment: 17-AAG (100 nM), aldosterone (100 nM), spironolactone (1 mM), dexamethasone (100 nM), RU486
(1 mM), Rosiglitazone (1 mM), T0070907 (3 mM) for 16 h. After hormone treatment, cells were washed with PBS and lysed with 200 ml of passive lysis
buffer (Promega). Luciferase activity was determined by using a luciferase kit (Promega). Luciferase activity was normalized for constitutive Renilla
luciferase. Values are given as mean 6 SD (n = 3), *p,0.05, **p,0.01. (D and E) 3T3-L1 preadipocytes were induced to differentiate in absence or
presence of spironolactone (1026 M) or RU486 (1026 M) alone or in combination with 17-AAG (100 nM) only for the first 3 days of differentiation
protocol. (D) Red oil staining (scale bar, 70 mm) and analysis of triglyceride content.(E) PPARc mRNA levels in 3T3-L1 preadipocytes after the first 3
days of differentiation.*p,0.05, **p,0.01 vs Control, #p,0.05, ##p,0.01 vs Spiro, up,0.05 vs RU486.
doi:10.1371/journal.pone.0094127.g005
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profile in mature adipocytes, we treated fully mature adipocytes
(day 10 after confluence) with 17-AAG for 48 hours. We found
that treated adipocytes presented a different profile compared to
control, with an significant reduction of IGFBP3, HGF, Lipocalin
2 and Leptin, but only a minor effect on Adiponectin, VEGF,
Rantes and Resistin (Figure 6D).
Discussion
Hsp90 blockers are frequently used to limit the function and
expression of steroid and nuclear receptors [6,7,8,29,30]. Given
the determinant role of nuclear receptors in adipogenesis, we
investigated the effects of two geldanamycin analogues, the
DMSO soluble 17-AAG and the water soluble 17-DMAG on
adipogenesis. In this report, we showed that geldanamycin
analogues prevented adipocyte differentiation by inhibiting the
adipogenic transcriptional program that led to the reduction of
lipid accumulation into the cell. These results are in line with very
recent observations showing an inhibitory effect of Hsp90 blockers
on 3T3-L1 differentiation [20,21]. These findings were strength-
ened by our in vivo experiment showing a limited BW gain and fat
mass expansion of 17-DMAG treated mice fed a HFD.
Geldanamycin is an inhibitor of the chaperone protein Hsp90.
It binds with high affinity to the ATP binding pocket of Hsp90 and
blocks the protein in its ADP-bound inactive status [31]. Hsp90
plays a crucial role in the ligand activation of steroid signaling
pathways such as the aldosterone and glucocorticoid signaling. We
and others have previously shown that geldanamycin analogues
prevent the hormonal-induced activation of nuclear receptors such
as MR and also GR by inducing their degradation via the
ubiquitin-proteasome system [6,7,8]. If PPARc is considered as
the master regulator of adipogenesis, both MR and GR are also
Figure 6. 17-AAG affects adipokines production. (A) 3T3-L1 preadipocytes were induced or not to differentiation. 24 h supernatants from
preadipocytes and mature adipocytes were collected and assessed for adipokines expression using an antibody adipokine array. The cytokine level
was determined by chemiluminescence detection and autoradiography. Among the 38 cytokines tested, 8 were up-regulated in mature adipocytes.
(B) Each dot of the array was quantified using Image J software. (C) 3T3-L1 preadipocytes were induced to differentiation in presence or absence of
17-AAG (100 nM) from the beginning of the differentiation process. The abundance of different adipokines mRNA was measured by quantitative RT-
PCR. (D) 3T3-L1 mature adipocytes were treated or not with 17-AAG (100 nM) for 48 h. The abundance of different adipokines mRNA was measured
by quantitative RT-PCR. Given are means (n = 3) relative to GAPDH 6 SD, *p,0.05, **p,0.01, ***p,0.001 compared to non-treated mature
adipocytes.
doi:10.1371/journal.pone.0094127.g006
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needed in the differentiation of adipocytes. However, their
respective roles in the process of adipogenesis remain unclear.
Whereas GR knock-down does not seem to have profound impact
on adipocyte conversion, MR knock-down or MR blockers
completely abolished lipid accumulation [10,32]. Furthermore,
unlike to GR, MR expression is induced during the preadipocyte
differentiation and obese mice models (ob/ob and db/db) display a
higher MR expression level compared to lean mice [14,33]. In this
study, we reported that activity of MR, and at a lower extent GR,
in early adipogenesis are crucial for a full development of the
maturation process of 3T3-L1 cells. We also demonstrated that the
selected dose of Hsp90 blocker (100 nM) dramatically reduced
PPARc and GR expression levels and inhibited the phosphory-
lation of MR. These expression levels changes in GR and PPARc,
but not MR, were confirmed in mice treated with 17-DMAG.
Nevertheless, the reporter gene assay allowed us to correlate the
effects of geldanamycin analogues on the expression of these
nuclear receptors with an inhibition of their transcriptional
activity.
In our preliminary animal study, treatment with 10 mg/kg/day
of 17-DMAG limited fat accumulation in mice fed a high fat diet
without any relevant side effects. Our findings are corroborated by
a recent study demonstrating that treatment with a lower dose of
geldanamycin (6.5 mg/kg/day) preserved kidney function of obese
mice fed a high fat diet [24]. Taken together, these observations
allow us to suggest that Hsp90 blockers not only inhibit
adipogenesis, but also prevent the negative effects of excessive
fat mass accumulation on kidney function. This could be explained
by the effects of geldanamycin analogues on the endocrine
function of adipose tissue. Excessive growth of adipose tissue leads
to disturbances of the adipokine profile, and this disregulation
plays a central role in the appearance of the obesity-related
metabolic disorders [34]. Here, we demonstrated in vitro that 17-
AAG modified the production of adipokines in a different manner
if it was administrated at the beginning of the differentiation
process or later during adipogenesis. In both conditions, we found
that Lipocalin 2, a direct target gene of MR, was down-regulated.
Lipocalin 2 is a biomarker for human acute kidney injury and it
has been shown to play an essential role for chronic kidney disease
progression in mice and humans [35,36].
Following our in vitro and in vivo experiments, the question arises
whether geldanamycin analogues effects occurred via a direct MR
and GR signaling down-regulation or via the disturbance of other
nuclear receptors bound to Hsp90. Nguyen et al. proposed that
PPARc protein destabilization is the main mechanism by which
Hsp90 inhibitors block the adipogenesis process [21]. However,
we have found that geldanamycin analogues could also interfere
with the induction of PPARc mRNA during adipocyte differen-
tiation as well as its induction by steroids. These observations
suggest that in addition to decrease the available pool of PPARc
protein, inhibition of Hsp90 also prevents the de novo-synthesis of
this transcription factor by inhibiting upstream signaling pathways.
The Androgen Receptor (AR) represents another nuclear receptor
that may be affected by Hsp90 inhibition. However, a potential
effect through AR is excluded given that inhibition of AR signaling
has no relevant effects on adipocyte differentiation in vitro [11,37],
but rather the deletion of AR gene in vivo increased susceptibility to
visceral obesity [38]. Further investigations will lead to definitively
elucidate the main cause of the anti-adipogenic effect of Hsp90
inhibitors. Given the numerous partners of this chaperone protein,
it seems clear that its inhibition leads to the disturbance of the
adipogenesis process at several steps. Furthermore, a full
characterization and large metabolic studies in suitable animal
models are required to confirm the efficiency of Hsp90 blockers on
excessive fat mass accumulation and related metabolic disorders
and the implication of glucocorticoids signaling in these effects.
In summary, our study demonstrated a powerful effect of
geldanamycin analogues consisting in the inhibition of adipocyte
differentiation and function in vitro and fat mass accumulation in
vivo. These effects were paralleled with an inhibition of MR, GR
and PPARc signaling in adipocytes. Our study adds additional
evidences and underlines the importance of glucocorticoids
signaling inhibition for the prevention of obesity and its related
metabolic complications.
Supporting Information
Figure S1 Geldanamycin Analogues inhibit lipid accu-
mulation in adipocytes. (A) At confluence, 3T3-L1 or 3T3-
F442A preadipocytes were induced to differentiation in presence
of an increasing dose of 17-AAG or 17-DMAG for 10 days. Lipid
accumulation was visualized under microscope after Oil-Red-O
staining. (B) The lipid accumulation was quantified after extraction
of the stained lipid and the absorbance measured at 520 nm. Data
are given as mean 6 SD (n= 3), *p,0.05, ***p,0.001.
(PDF)
Figure S2 17-DMAG limits high fat diet-induced body
weight gain. Two groups of mice HFD (n= 7) and HFD+17-
DMAG (n= 8) were fed a HFD for 33 days and daily injected
intraperitoneally with PBS or with 10 mg/kg of BW 17-DMAG.
One group as control ND (n= 4) were fed a standard chow. The
body weight was measured every 3 days.
(PDF)
Figure S3 17-DMAG prevents adipocyte hypertrophy.
Histological analysis of the inguinal adipose tissue fixed and
stained with hematoxylin and eosin. Visualized under light
microscope (X10). Scale bar = 200 mm.
(PDF)
Figure S4 Effects of blockers on adipocyte MR expres-
sion. (A) 3T3-L1 preadipocytes were induced to differentiation
with or without spironolactone (1025 M) for 10 days. Cell lysates
were analyzed by immunoblotting using antibodies against MR
and actin as a loading control. (B) 3T3-L1 preadipocytes were
induced to differentiation. At day 2 cells were treated with an
increasing dose of 17-AAG for 24 h. Cell lysates were analyzed by
immunoblotting using antibodies against MR, GR and actin as a
loading control.
(PDF)
Figure S5 17-AAG prevents steroid induction of PPARc.
3T3-L1 preadipocytes were induced to differentiation in presence
or absence of 17-AAG (100 nM), aldosterone (10 nM) or
dexamethasone (100 nM) for 10 days. The abundance of PPARc
mRNA was measured by quantitative RT-PCR. Given are means
relative to GAPDH of 2 experiments performed in triplicate 6
SD, **p,0.01.
(PDF)
Table S1 Primer sequences used in the quantitative
PCR experiments.
(PDF)
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